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A B S T R A C T
Background
Vitamin E occurs naturally in the diet. It has several biological activities, including functioning as an antioxidant to scavenge toxic free
radicals. Evidence that free radicals may contribute to the pathological processes behind cognitive impairment has led to interest in the
use of vitamin E supplements to treat mild cognitive impairment (MCI) and Alzheimer’s disease (AD). This is an update of a Cochrane
Review first published in 2000, and previously updated in 2006 and 2012.
Objectives
To assess the efficacy of vitamin E in the treatment of MCI and dementia due to AD.
Search methods
We searched the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (ALOIS), the Cochrane Library,
MEDLINE, Embase, PsycINFO, CINAHL, LILACS as well as many trials databases and grey literature sources on 22 April 2016
using the terms: “Vitamin E”, vitamin-E, alpha-tocopherol.
Selection criteria
We included all double-blind, randomised trials in which treatment with any dose of vitamin E was compared with placebo in people
with AD or MCI.
Data collection and analysis
We used standard methodological procedures according to the Cochrane Handbook for Systematic Reviews of Interventions. We rated the
quality of the evidence using the GRADE approach.Where appropriate we attempted to contact authors to obtain missing information.
Main results
Four trials met the inclusion criteria, but we could only extract outcome data in accordance with our protocol from two trials, one in
an AD population (n = 304) and one in an MCI population (n = 516). Both trials had an overall low to unclear risk of bias. It was not
possible to pool data across studies owing to a lack of comparable outcome measures.
In people with AD, we found no evidence of any clinically important effect of vitamin E on cognition, measured with change from
baseline in the Alzheimer’s Disease Assessment Scale - Cognitive subscale (ADAS-Cog) over six to 48 months (mean difference (MD)
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-1.81, 95% confidence interval (CI) -3.75 to 0.13, P = 0.07, 1 study, n = 272; moderate quality evidence). There was no evidence of a
difference between vitamin E and placebo groups in the risk of experiencing at least one serious adverse event over six to 48 months (risk
ratio (RR) 0.86, 95% CI 0.71 to 1.05, P = 0.13, 1 study, n = 304; moderate quality evidence), or in the risk of death (RR 0.84, 95%
CI 0.52 to 1.34, P = 0.46, 1 study, n = 304; moderate quality evidence). People with AD receiving vitamin E showed less functional
decline on the Alzheimer’s Disease Cooperative Study/Activities of Daily Living Inventory than people receiving placebo at six to 48
months (mean difference (MD) 3.15, 95% CI 0.07 to 6.23, P = 0.04, 1 study, n = 280; moderate quality evidence). There was no
evidence of any clinically important effect on neuropsychiatric symptoms measured with the Neuropsychiatric Inventory (MD -1.47,
95% CI -4.26 to 1.32, P = 0.30, 1 study, n = 280; moderate quality evidence).
We found no evidence that vitamin E affected the probability of progression from MCI to probable dementia due to AD over 36
months (RR 1.03, 95% CI 0.79 to 1.35, P = 0.81, 1 study, n = 516; moderate quality evidence). Five deaths occurred in each of the
vitamin E and placebo groups over the 36 months (RR 1.01, 95% CI 0.30 to 3.44, P = 0.99, 1 study, n = 516; moderate quality
evidence). We were unable to extract data in accordance with the review protocol for other outcomes. However, the study authors
found no evidence that vitamin E differed from placebo in its effect on cognitive function, global severity or activities of daily living .
There was also no evidence of a difference between groups in the more commonly reported adverse events.
Authors’ conclusions
We found no evidence that the alpha-tocopherol form of vitamin E given to people with MCI prevents progression to dementia, or
that it improves cognitive function in people with MCI or dementia due to AD. However, there is moderate quality evidence from a
single study that it may slow functional decline in AD. Vitamin E was not associated with an increased risk of serious adverse events or
mortality in the trials in this review. These conclusions have changed since the previous update, however they are still based on small
numbers of trials and participants and further research is quite likely to affect the results.
P L A I N L A N G U A G E S U M M A R Y
The use of vitamin E in the treatment of mild cognitive impairment and Alzheimer’s disease (AD)
Background
Vitamin E is found in a variety of foods, including vegetable oils and fats, nuts and seeds. Some animal and non-interventional studies
have suggested it might have a role in the prevention or treatment of Alzheimer’s disease (AD). However, evidence has linked vitamin
E with potentially serious side effects and even an increased risk of death. In this review, we looked for evidence about the effect of
vitamin E on people who had either dementia due to AD or milder problems with memory or thinking (mild cognitive impairment
or MCI). People with MCI have an increased risk of developing dementia.
Included trials
We searched for clinical trials published up to April 2016 which had randomly allocated people with dementia due to AD or with
MCI to treatment with vitamin E supplements or a placebo (pretend treatment). We found three trials that investigated the effects of
vitamin E on people with AD, but we could extract data from only one of these trials (304 participants). We found only one trial with
516 participants which investigated the effects of vitamin E on people with MCI. The quality of these two trials was generally good.
Results
Vitamin E did not reduce the number of people with MCI who developed dementia over three years. We also found no evidence that
vitamin E improved cognition (e.g. learning and memory) in people with MCI or with dementia due to AD. One trial found that
people with dementia due to AD who took vitamin E could manage daily activities (e.g. bathing and dressing) better than people who
took placebo. There was no evidence from these trials that vitamin E caused significant harm to participants, but these types of trials
are not the best way to look for harmful effects unless the effects are very common. Because all the results came from single trials, it is
likely that further research could lead to different conclusions.
Conclusion
From limited evidence, we found nothing to suggest that there are either benefits or harms from vitamin E supplements. As the quality
of evidence was only moderate, further trials are needed to confirm the findings. It is possible that different types or doses of vitamin
E might have different effects.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Vitamin E (capsules 2000 IU/day in 2 divided doses) compared to placebo for people with Alzheimer’s disease
Patient or population: people with Alzheimer’s disease
Settings: mult icentre, US
Intervention: vitamin E (capsules 2000 IU/ day in 2 divided doses)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Vitamin E (capsules
2000 IU/day in 2 di-
vided doses)
Cognitive function
LS mean change f rom
baseline using the
ADAS-Cog
Scale f rom: 0 to 70
Follow-up: 6 to 48
months
The LS mean change
f rom baseline in cogni-
t ive funct ion in placebo
group was 7.78
The LS mean change
f rom baseline in cogni-
t ive funct ion in the in-
tervent ion group was 1.
81 lower
(3.75 lower to 0.13
higher)
- 272
(1 study)
⊕⊕⊕©
Moderate1
Higher scores repre-
sent worse cognit ive
funct ion.
A 4-point dif f erence
in ADAS-cog has been
considered the MCID
Adverse events
Number of part icipants
report ing ≥ 1 serious
adverse event
Follow-up: 6 to 48
months
625 per 1000 538 per 1000
(444 to 656)
RR 0.86
(0.71 to 1.05)
304
(1 study)
⊕⊕⊕©
Moderate1
-
Deaths
Number of deaths
Follow-up: 6 to 48
months
204 per 1000 171 per 1000
(106 to 273)
RR 0.84
(0.52 to 1.34)
304
(1 study)
⊕⊕⊕©
Moderate1
-
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Activities of daily living
LS mean change f rom
baseline using the
ADCS-ADL
Scale f rom: 0 to 78
Follow-up: 6 to 48
months
The LS mean change
f rom baseline in act ivi-
t ies of daily living in the
placebo group was - 16.
96
The LS mean change
f rom baseline in act ivi-
t ies of daily living in the
intervent ion group was
3.15 higher
(0.07 to 6.23 higher)
- 280
(1 study)
⊕⊕⊕©
Moderate1
Higher scores repre-
sent better act ivit ies of
daily living.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
ADAS-Cog: Alzheimer Disease Assessment Scale - Cognit ive Subscale; ADCS-ADL: Alzheimer’s Disease Cooperat ive Study/ Act ivit ies of Daily Living Inventory;CI: conf idence
interval; LS: least square; MCID: minimum clinically important dif f erence; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Quality downgraded one level due to imprecision. Evidence f rom a single study of modest size. This is supported by
dichotomous data not reaching the opt imal information size criterion (assuming α of 0.05, and β of 0.2) (Guyatt 2011).
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B A C K G R O U N D
Description of the condition
Dementia due to Alzheimer’s disease (AD) is a progressive neu-
rodegenerative condition in which people develop deficits in mul-
tiple cognitive domains, including memory, language and execu-
tive functioning, as well as a variety of emotional and behavioural
symptoms. This leads to progressive functional impairment. AD
causes huge emotional and financial burden to people, carers, and
health and social care systems. Current treatments for AD have
limited efficacy and cannot prevent progression of the condition.
It is projected that 5.2% of the world’s population will have de-
mentia by 2050, equating to a worldwide prevalence of 131.5 mil-
lion cases (Prince 2015).
Mild cognitive impairment (MCI) is a condition of cognitive
deficits which are not accompanied by significant impairment in
the performance of activities of daily living and hence do not meet
the diagnostic criteria for dementia. People with MCI are at in-
creased risk of developing dementia (Ganguli 2011), although this
is not considered inevitable (Bruscoli 2004). In 2011, it was esti-
mated that between 10% and 20% of people over the age of 65
years meet criteria for MCI (Petersen 2011).
Description of the intervention
VitaminE is a generic term for a group of eight naturally occurring,
fat-soluble chemical derivatives of tocopherol and tocotrienol. It
occurs naturally in a variety of food substances including vegetable
oils and fats, and in nuts and seeds, such as almonds and sunflower
seeds. Alpha-tocopherol is themost commonly studied compound
and it has been the only form of vitamin E used in clinical trials
in AD. According to the Food and Nutrition Board (FNB) at
the Institute of Medicine of the National Academies (US), the
recommended daily allowance for men and women over 14 years
of age is 22.4 IU (15 mg of alpha-tocopherol) (National Academy
of Sciences 2000).
VitaminE has a number of biological activities which vary with the
form of vitamin E (Boccardi 2016). One of its functions is to act
as a scavenger of free radicals by working as an antioxidant (Uneri
2006). Oxygen free radicals contain oxygen atoms with unpaired
electrons and are highly reactive, damaging proteins, DNA and
cell membranes unless rapidly ’quenched’ by antioxidants. They
are produced as by-products of the body’s metabolism as well as by
radiation. As vitamin E is lipophilic, it can protect cell membranes
and plasma lipoproteins from peroxyl radicals, which react prefer-
entially with vitamin E (Traber 2011). In particular, vitamin E is
thought to inhibit the process of lipid peroxidation, which dam-
ages the polyunsaturated fatty acids essential to the integrity of cell
membranes. Vitamin E’s activity in protecting against the harmful
effects of free radicals may be measured indirectly by assessing the
state of the antioxidant-oxidant system. Endogenous antioxidants
such as glutathione provide an indication of the antioxidant sta-
tus while the oxidised form of glutathione, glutathione disulphide
(GSSG), and malondialdehyde (MDA)may provide an indication
of the oxidative stress status and in particular lipid peroxidation.
High doses of vitamin E (over 3000 IU/day) are considered toxic,
and have been implicated in a variety of symptoms including fa-
tigue, gastrointestinal cramps and diarrhoea. Further, there is an
increasing body of evidence that vitamin E supplementation can
cause adverse effects, even at lower doses. For example, vitamin E
increases bleeding tendency and can potentiate the effect of aspirin
(Steiner 1995). One meta-analysis found that vitamin E supple-
mentation, while reducing risk of ischaemic stroke by 10%, in-
creased the risk of haemorrhagic stroke by 22% (Schürks 2010).
Evidence from the Selenium and Vitamin E Cancer Prevention
Trial (SELECT) suggests that daily supplementation with vitamin
E 400 IU in healthy men may significantly increase the risk of
prostate cancer (Klein 2011), and there is evidence from theHeart
Outcomes Prevention Evaluation (HOPE) trial that vitamin E
supplementation increases the risk of heart failure and hospitali-
sation for heart failure in people over 55 years of age with diabetes
mellitus and vascular disease (Lonn 2005). Miller 2005 carried
out a meta-analysis of 19 clinical trials testing vitamin E alone
or in combination with other supplements. The median dose of
vitamin E in these trials was 400 IU/day although the maximum
dose was up to 2000 IU/day. The authors reported a statistically
significant dose-dependent relationship between vitamin E intake
and all-cause mortality. One Cochrane meta-analysis also found
that vitamin E given singly or combined with other antioxidants
significantly increased mortality in 26 trials (risk ratio (RR) 1.04)
(Bjelakovic 2010).
How the intervention might work
There are both theoretical arguments and empirical findings to
suggest that free radical damage may be one of the mechanisms
causing neuronal degeneration in a range of conditions includ-
ing ageing, MCI and AD. This evidence was summarised by
Grundman 2000. Many studies have found evidence of increased
level of oxidative damage to neurons and mitochondrial DNA in
AD and MCI (Butterfield 2002; Hensley 1995; Marcus 1998;
Mecocci 1994;Mecocci 2004;Wang 2005;Wang 2006). Antioxi-
dants, including vitamin E, improve cognitive functioning of aged
rodents (Socci 1995), and protect against the effects of brain is-
chaemia (Hara 1990) and of some neurotoxins (Wortwein 1994).
Transgenicmice overexpressing the amyloid precursor protein, im-
plicated in AD, showed accelerated age-associated brain degener-
ation (Hsiao 1995). Vitamin E can delay this deterioration (Behl
1992; Koppal 1998; Zhou 1996), and decrease oxidative DNA
damage (Boothby 2005).
Central nervous tissue contains a high proportion of fatty mate-
rial (lipid), and since vitamin E is fat-soluble it can readily enter
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the brain (Vatassery 1988). In older-adult population-based stud-
ies, there have been reports of an association between low blood
levels of vitamin E and impaired cognitive function (Cherubini
2005; Perrig 1997). Mean levels of vitamin E in the blood and
cerebrospinal fluid of people with AD were reported to be lower
than normal in several reports (Jeandel 1989; Jimenez-Jimenez
1997; Polidori 2002; Tohgi 1994; Zaman 1992), though not in
all (Ahlskog 1995). Lower levels of both forms of vitamin E - to-
cotrienols and tocopherols - have been observed in the plasma of
people with AD and MCI (Mangialasche 2012). However, lower
levels of vitamin E in AD may be a consequence of the disease
rather than a cause of it, due in part to an overall decreased gen-
eral dietary intake especially as the disease advances (Tabet 2001;
Tabet 2002).
Results from clinical trials of vitamin E in non-AD neurodegen-
erative disorders have not been promising. For example, neither
people with Parkinson’s disease (Parkinson’s SG1993; Pham2005)
nor Huntington’s disease (Peyser 1995) have shown a significant
overall benefit from vitamin E supplementation. In this review, we
focused specifically on the role of vitamin E in the treatment of
AD and MCI.
Why it is important to do this review
It is estimated that 46.8 million people worldwide have a diag-
nosis of dementia, and this is predicted to rise to 131.5 million
cases by 2050 (Prince 2015), with AD being the most prevalent
subtype. At present, there is no effective treatment for MCI or for
dementia due to AD. Vitamin E continues to be used by some
people as a non-prescription supplement mainly because of its
widely reported antioxidant properties and some previous posi-
tive findings. However, due to the potential health risks of taking
vitamin E, it is important to determine whether vitamin E is an
effective treatment of AD andMCI. This is an update of an earlier
Cochrane Review, which was originally published in 2000 and
was last updated in 2012. This review involved an updated search
of the literature as well as changes to the conclusion, which better
reflect emerging findings from vitamin E clinical trials in AD.
O B J E C T I V E S
To assess the efficacy of vitamin E in the treatment of MCI and
dementia due to AD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised, double-blind trials in which vitamin
E was compared with placebo in the treatment of people with
MCI or dementia due to AD, or both.
Types of participants
Participants with AD were diagnosed with probable AD ac-
cording to internationally accepted diagnostic criteria including
NINCDS-ADRDA (National Institute ofNeurological andCom-
municative Disorders and Stroke-Alzheimer’s Disease and Related
Disorders Association (McKhann 1984), Diagnostic and Statisti-
cal Manual of Mental Disorders, Fourth Edition (DSM-IV) (APA
1994), or International Statistical Classification of Diseases and
RelatedHealth Problem, TenthRevision (ICD-10). In the absence
of consensus criteria forMCI, we acceptedMCI defined according
to published criteria such as those by Petersen 2005, or any other
criteria with face validity. If only a subset of the study population
was eligible for inclusion, then we sought and included data relat-
ing only to the eligible participants.
Types of interventions
We included studies using any dosage of vitamin E or any of
its constituent tocopherols or tocotrienols. A placebo comparator
was required. Co-administration of another drug with vitamin
E was permitted if the same drug was also taken by the placebo
group. There was no restriction on the dosage, mode of delivery
or duration of the vitamin E intervention.
Types of outcome measures
We sought data on the primary and secondary outcomes listed
below. For continuous outcomes, we included only data derived
from validated, published scales.
Primary outcomes
• For MCI studies, development of, or time to development
of, possible or probable AD.
• Cognitive function.
• Adverse events
• Death.
Secondary outcomes
• Global measure of dementia severity and deterioration.
• Behavioural disturbance.
• Mood.
• Activities of daily living.
• Carer burden.
• Quality of life.
• Permanent physical disability.
• Institutionalisation.
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Search methods for identification of studies
Electronic searches
We searched ALOIS (www.medicine.ox.ac.uk/alois) - the
Cochrane Dementia and Cognitive Improvement Group’s Spe-
cialized Register on 22 April 2016. The search terms used were:
“Vitamin E”, vitamin-E, alpha-tocopherol.
ALOIS is maintained by the Trials Search Co-ordinator of the
CochraneDementia and Cognitive ImprovementGroup and con-
tains studies in the areas of dementia prevention, dementia treat-
ment and cognitive enhancement in healthy people. The studies
are identified from:
• monthly searches of a number of major healthcare
databases: MEDLINE, Embase, CINAHL, PsycINFO and
LILACS;
• monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan’s Trial Register); the World Health Organization
(WHO) portal (which covers ClinicalTrials.gov; ISRCTN; the
Chinese Clinical Trials Register; the German Clinical Trials
Register; the Iranian Registry of Clinical Trials and the
Netherlands National Trials Register, plus others);
• quarterly searches of the Cochrane Library’s Central
Register of Controlled Trials (CENTRAL);
• six-monthly searches of a number of grey literature sources:
ISI Web of Knowledge Conference Proceedings; Index to Theses
and Australasian Digital Theses.
To view a list of all sources searched for ALOIS see About ALOIS
on the ALOIS website.
Details of the search strategies used for the retrieval of reports of
trials from the healthcare databases, CENTRAL and conference
proceedings can be viewed in the ’methods used in reviews’ sec-
tion within the editorial information about the Dementia and
Cognitive Improvement Group.
Additional searches were performed in the sources listed above to
cover the timeframe from the last searches performed for ALOIS
to ensure that the search for the review was as up-to-date and as
comprehensive as possible. The search strategies used can be seen
in Appendix 1.
Searching other resources
We reviewed reference lists of included studies to identify any
additional studies.
Data collection and analysis
Selection of studies
Two review authors (NF and DL) independently examined the
title and abstract of the papers identified by the search and selected
and retrieved them for their relevance to the review. We resolved
any disagreements concerning inclusion by discussion among all
review authors until a decision was made.
Data extraction and management
Two review authors (NF and DL for descriptive data, NF and NT
for outcome data) independently extract data for all authors. We
attempted to collect the following data:
• report - author, year and source of publication;
• study - study setting;
• participants - demographics, diagnostic criteria for AD or
MCI, exclusion criteria, other concomitant medical conditions
or medications that may affect cognition;
• research design and features - sampling mechanism,
treatment assignment mechanism, blinding, dropout rates,
length of follow-up, pertinent design features (e.g. cross-over
design);
• intervention - type, duration, dose, timing, mode of
delivery;
• outcome measures;
• results - number of participants randomised, outcome data.
For each outcome measure, we sought data on every participant
randomisedWepreferred intention-to-treat (ITT) data but if these
were not available, we extracted data on participants who com-
pleted treatment. We did not extract data for any non-randomised
titration periods or any open-label follow-on phases.
For continuous data, we extracted the means, standard deviation
(SD) and number of participants in each treatment group at each
time point. We extracted change from baseline data if endpoint
data were unavailable. For binary data, the data extracted was
the number of participants with each outcome in each treatment
group at each time point. For ordinal data, there were two possi-
ble approaches. If ordinal scale data appeared to be approximately
normally distributed or if the analysis that the investigators per-
formed suggested that parametric tests were appropriate, then ewe
treated the outcome measures as continuous data. The second ap-
proach, which may not exclude the first, was to concatenate into
two categories that best represent the contrasting states of interest,
and to treat the variable as binary. For time-to-event data, we used
a hazard ratio (HR).
Assessment of risk of bias in included studies
Two review authors (NF and DL) assessed risk of bias for each
included study independently. Thiswas assessed based on guidance
from theCochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We assessed the following criteria:
• sequence generation;
• allocation concealment;
• blinding (participants);
• blinding (investigators);
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• incomplete outcome reporting;
• selective outcome reporting.
For each study, we gave a risk of bias rating (’Low risk’, ’Unclear
risk’ or ’High risk’) for each of the above criteria. Empirical re-
search has shown that lack of adequate allocation concealmentmay
be associated with bias. Trials with unclear concealment measures
have been shown to yieldmore pronounced estimates of treatment
effects than trials that have taken adequate measures to conceal
allocation schedules, but less pronounced than inadequately con-
cealed trials (Chalmers 1983; Schulz 1995). Thus, we included
trials if they conformed to ’Low risk’ or ’Unclear risk’ allocation
risk categories, while we excluded trials falling into the ’High risk’
category.
Measures of treatment effect
For studies with continuous outcome measures, we calculated
mean differences (MD) or standardised mean differences (SMD)
with 95% confidence intervals (CI). For binary outcome mea-
sures, we calculated RRs. For time-to-event outcomemeasures, we
calculated HRs.
Unit of analysis issues
The participant was the unit of analysis.
Dealing with missing data
An ITT analysis was carried out where possible. In cases where
only completers’ data were available, we explored the impact of the
missing data on the findings, where possible. When appropriate,
the review authors contacted relevant study authors to request
missing information.
Assessment of heterogeneity
Owing to the clearly significant clinical and methodological het-
erogeneity between studies, we performed no statistical tests for
heterogeneity. As such, data did not lend itself to performing a
meta-analysis. However, we carried out critical interpretive syn-
thesis of data for individual studies.
Assessment of reporting biases
There were an insufficient number of studies identified tomake an
overall quantitative assessment. We assessed biases for individual
studies.
Data synthesis
It was not possible to synthesise and compare data across studies
as there were no comparable outcome measures. We carried out
a critical interpretive synthesis of data for individual studies sepa-
rately. We included ’Summary of findings’ tables.
Subgroup analysis and investigation of heterogeneity
Although not specified in the protocol, we extracted and reported
data for a subgroup analysis carried out in one included study. The
subgroups were participants who did or did not show a decline in
markers of oxidative stress in response to vitaminE treatment. This
subgroup was considered important to include as a reduction of
oxidative stress is thought to be the mechanism by which vitamin
E may affect cognition.
Sensitivity analysis
Sensitivity analysis was planned if a sufficient number of compa-
rable studies were identified.
Presentation of results - ’Summary of findings’ tables
Weused theGRADE approach to assess the quality of the support-
ing evidence behind the treatment effects presented in this review
(Guyatt 2011). For each comparison, we presented key outcomes
in a ’Summary of findings’ table including, for each outcome, a
summary of the amount of data, the magnitude of the effect size
and the quality of the evidence.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies tables.
Results of the search
Only four trials met the inclusion criteria: Dysken 2014; Lloret
2009; Petersen 2005; and Sano 1996. Three were trials of alpha-
tocopherol (vitamin E) for the treatment of dementia due to AD
(Dysken 2014; Lloret 2009; Sano 1996) and one was a trial of
alpha-tocopherol to delay progression from amnestic MCI to de-
mentia (Petersen 2005). See Figure 1 for the study flow diagram
of included studies.
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Figure 1. Study flow diagram for study for the search April 2016.
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Included studies
Treatment of dementia due to Alzheimer’s disease
The primary purpose of the first treatment study was to determine
whether alpha-tocopherol (vitamin E), selegiline (a monoamine
oxidase inhibitor) or a combination of the two agents would slow
the clinical deterioration associated with AD (Sano 1996). There
were four groups: placebo, vitamin E (2000 IU total daily dose
divided into two doses), selegiline and selegiline plus vitamin E.
The study recruited 341 participants with a diagnosis of proba-
ble AD dementia of moderate severity (Clinical Dementia Rating
(CDR) 2 (Berg 1988)) from 23 centres in the US. We considered
only the placebo (n = 84) and vitamin E (n = 85) groups in this
review. Assessments were conducted one month after enrolment
and at three-monthly intervals for two years. The primary out-
come was the survival time to any one of four end points; death,
institutionalisation, change in severity of dementia to a CDR of
three or loss of two basic activities of daily living. After the primary
end point was reached, every effort was made to continue further
assessment of the secondary outcomes if possible. The secondary
outcomes were the Cognitive section of the Alzheimer’s Disease
Assessment Scale (ADAS-Cog) (Rosen 1984), the Mini-Mental
State Examination (MMSE) (Folstein 1975), the Blessed Demen-
tia Scale (BDS) (Blessed 1968), theDependence Scale (DS) (Stern
1994), the Behavior Rating Scale for Dementia (BRSD) (Tariot
1995), and adverse events. The primary analysis compared sur-
vival to end point for each of the three treatment groups in com-
parison with the placebo group, using Kaplan-Meier estimation
and log-rank tests with no correction for other factors or variables,
and the Cox proportional hazards model including covariates. A
small number of participants were lost to follow-up without hav-
ing reached a primary end point (placebo 6/84, vitamin E 8/85).
The purpose of the second treatment study was to explore the
effects of vitamin E on AD progression and markers of oxida-
tive stress (Lloret 2009). Vitamin E 800 IU or placebo was given
daily for six months. There were 57 participants diagnosed with
probable AD. All AD participants were taking a cholinesterase
inhibitor and were not taking any other antioxidant medication.
Assessments were conducted on the first day of enrolment and
after six months. Oxidative stress was assessed in two ways. The
firstmethod used blood concentrations of the oxidised glutathione
molecule, GSSG, with greater levels indicating greater oxidative
stress. GSSG was also assessed as a ratio with the antioxidant
molecule, glutathione. The second method measured the blood
marker MDA as a marker of lipid peroxidation, which is a strong
indicator of oxidative damage. AD progression was measured by
theClockDrawing Test (Sunderland 1989), the BDS andMMSE.
The primary analysiswas to compare performance on the cognitive
tasks in relation to the effects of vitamin E on oxidative stress. The
effects of vitamin E on oxidative stress markers were investigated
using a Mann-Whitney test to compare GSSG and MDA values
at the beginning and the end of the study in both the placebo
and active treatment groups. Vitamin E-treated participants were
divided into responders and non-responders according to whether
vitamin E was effective or not in reducing markers of oxidative
stress. The responder, non-responder and placebo group means
were compared using a Kruskal-Wallis test. Comparison between
groups was also undertaken following removal of participants with
cerebrovascular disease. To determine the effect of modifying ox-
idative stress on cognitive performance, the relationship between
MMSE change and GSSG change in participants treated with vi-
tamin E was assessed using Spearman’s coefficient of correlation.
We contacted two authors of the Lloret 2009 study for additional
information, but following an initial response from one author,
we received no additional responses.
The purpose of the third treatment study was to determine if al-
pha tocopherol (vitamin E), memantine, or both slowed the pro-
gression of mild to moderate AD (Dysken 2014). In a double-
blind, placebo-controlled randomised controlled trial (RCT), 613
people with mild to moderate AD were randomly assigned to one
of four groups: alpha tocopherol (2000 IU total daily divided into
two doses), memantine 20mg/day, alpha tocopherol plus meman-
tine or placebo. We considered only the placebo (n = 152) and
vitamin E (n = 152) groups in this review. All participants were
recruited in the US and had a diagnosis of possible or probable
AD of mild to moderate severity, as defined by a MMSE score be-
tween 12 and 26. Duration of treatment ranged from six months
to four years and participants were assessed every six months. The
primary outcome was the Alzheimer’s Disease Cooperative Study/
Activities of Daily Living (ADCS-ADL) scale (Galasko 2006).
Secondary outcomes were the ADAS-Cog, Neuropsychiatric In-
ventory (NPI) (Cummings 1994), the Caregiver Activity Survey
(CAS) (Davis 1997), the DS and adverse events. Participants and
their carers were asked specifically about participant falls, syncope
and congestive heart failure as these were linked to high-dose al-
pha tocopherol in previous trials (Lonn 2005; Sano 1996). Seri-
ous adverse events were coded on the basis of Medical Dictionary
for Regulatory Activities. A longitudinal repeated-measure mixed-
effects model adjusted for medical centre as a random effect and
for baseline ADCS-ADL.
Prevention of progression of cognitive impairment
The primary purpose of the single MCI study was to determine
whether treatment with vitamin E 2000 IU/day or donepezil in
people with the amnestic form of MCI decreased the conversion
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rate into dementia due to AD (Petersen 2005). There were three
treatment groups: vitamin E, donepezil and placebo. All partici-
pants were also taking a multivitamin. This review included the
vitamin E and the placebo groups only. Out of 769 participants
enrolled from 69 sites in the US and Canada, 516 received ei-
ther placebo or vitamin E. The secondary outcomes were scores
on various measures: the MMSE (Folstein 1975), ADAS-Cog (
Rosen 1984), CDR (Sum of Boxes), the Alzheimer’s Disease As-
sessment ScaleMild Cognitive Impairment Activities of Daily Liv-
ing (ADCS-MCI-ADL) scale, the Global Deterioration Scale, a
neuropsychological battery and adverse events. For further details
about the study design refer to the Characteristics of included
studies table.
The relevant primary analysis in the paper used the Cox propor-
tional hazards model to determine whether there was a significant
reduction in time to progression to AD among participants treated
with vitamin E compared with participants given placebo. Partic-
ipants were included on an ITT basis. Several baseline variables
were included in the analysis as covariates. The secondary out-
comes were examined using analysis of covariance for the change
in scores without correction for multiple comparisons. Missing
values were imputed using a projection method considered appro-
priate for assessing responses among people with neurodegenera-
tive diseases (Aisen 2003).
Excluded studies
Following the latest search (April 2016), we initially excluded 46
articles based on the screening of the abstract and title. Of the 11
remaining articles, we excluded one because it did not use a suitable
control intervention for our question (Naeini 2014), two because
the study population was ineligible (Kryscio 2013a; MacPherson
2012), and three because they were not RCTs (Corbett 2014;
Evans 2014; Hermann 2014). The five remaining articles all de-
scribed one study which was eligible for inclusion (Dysken 2014),
however, we subsequently excluded two because they were identi-
fied as duplicates. Details of the excluded studies are provided in
Characteristics of excluded studies table.
Risk of bias in included studies
See Figure 2 for the summary of the risk of bias, and Figure 3
for the ’Risk of bias’ graph. See Characteristics of included studies
table for further details of included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
We judged that all four studies had a low risk of bias in terms of
random sequence generation.
Only Dysken 2014 sufficiently described their method of alloca-
tion concealment. In the other three studies, the means of ensur-
ing allocation concealment was unclear. However, we considered
it sufficiently likely that allocation was concealed to include the
studies.
Blinding
All studies report that they were double-blinded, though no study
described how this was maintained throughout the studies or
whether blinding was successful. However, Dysken 2014 did use
placebo capsules with identical appearance to the vitamin E cap-
sules, so we considered this to have a low risk of bias. We judged
the remaining studies to have an unclear risk of performance bias.
We considered all studies at unclear risk of detection bias because
of a lack of information on blinding of outcome assessors.
Incomplete outcome data
Missing data was balanced across groups in Dysken 2014, thus
we judged risk of bias to be low. Petersen 2005 reported using an
ITT analysis with an appropriate imputation method to deal with
missing data and stated that demographic and neuropsychological
outcomes did not differ significantly between missing and non-
missing participants. However, it was difficult to tell how the au-
thors had handled data from participants who had developed de-
mentia and switched to open-label donepezil. Only 42% of partic-
ipants randomised to vitamin E and 46% randomised to placebo
completed the study on their allocated treatment. We judged the
study to have an unclear risk of attrition bias. Sano 1996 reported
the attrition rate but did not give reasons. In addition, Sano 1996
only reported attrition up to the point a participant reached one
of their primary end points, therefore we judged it to be at high
risk of bias for our outcomes of interest. Lloret 2009 reported a
very high attrition rate and did not give reasons; we judged it to
be at high risk of bias.
Selective reporting
All studies reported outcomes stated in their protocol although
often in insufficient detail for our purposes. Lloret 2009 tended to
report significance values alone, withoutmeans and SDs. Similarly,
Sano 1996 did not report SDs for the changes in score of their
secondary outcomes. Thus, we judged the Lloret 2009 and Sano
1996 studies to have an unclear risk of bias in this domain. We
judged the remaining studies to have a low risk of reporting bias.
Other potential sources of bias
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We found no other sources of bias.
Effects of interventions
See: Summary of findings for the main comparison Vitamin E
(capsules 2000 IU/day in two divided doses) compared to placebo
for people with Alzheimer’s disease; Summary of findings 2
Vitamin E (capsules 2000 IU/day in two divided doses) compared
to placebo for people with mild cognitive impairment
Vitamin E for dementia due to Alzheimer’s disease
Three studies assessed the efficacy of vitamin E in people with
dementia due to AD (Dysken 2014; Lloret 2009; Sano 1996).
For a summary of findings related to the treatment of AD, see
Summary of findings for the main comparison.
Sano 1996 had four treatment groups of which the groups receiv-
ing placebo only and vitamin E only were relevant to this review.
Six of 84 participants in the placebo group and 8 of 85 participants
in the vitamin E group were lost to follow-up without reaching
one of the predefined primary end points of death, institutionali-
sation, change in severity of dementia to a CDR score of three, or
loss of two basic activities of daily living, but there was no infor-
mation on the time points at which these participants were lost or
on how many participants were lost to follow-up after a primary
end point.
Lloret 2009 divided participants treated with vitamin E into two
groups depending on changes in oxidative stress markers with
treatment. These groups had not been defined in advance of data
collection. Participants who showed a decrease in GSSG values of
more than 10 nmol/mL of blood after six months of vitamin E
treatment were termed ’responders’ and participants who did not
were termed ’non-responders’. They reported ’completers’ results
only (33/57 randomised participants).
Dysken 2014 had four treatment groups, but we evaluated only
data for the vitamin E and placebo groups for this review (Dysken
2014). There was a wide range of durations of follow-up within
the trial (six to 48 months), with participants completing at least
one follow-up being included in the analysis. The final analysis
included140/152 (92.1%)participants in the vitaminE group and
140/152 (92.1%) participants in the placebo group. The authors
calculated a least squares (LS) mean change from baseline in each
treatment group and reported this with its standard error (SE).
Dysken 2014 also reported results as amean annual rate of change.
For each relevant continuous outcome variable, we extracted the
LS mean change from baseline, and derived SDs from reported
SEs. We then calculated the MD (with 95% CI) between vitamin
E and placebo groups.
Primary outcomes
Cognitive function
We were unable to extract the data we had specified for cognitive
function for Sano 1996. Although the ADAS-Cog and MMSE
were secondary outcomes in the trial, only mean change scores to
the time point where a participant was last assessed were reported
and participants had been assessed over varying and unidentified
time spans. SDs were not reported. The authors reported that
changes from baseline score on the MMSE and the ADAS-Cog
did not differ significantly among the four groups.
Lloret 2009 measured cognition using the MMSE and the Clock
Drawing Test, though we were unable to extract the data. The
authors did not reportmeans and SDs of their cognitive outcomes.
There were no data on cognitive measures in the vitamin E-treated
group as a whole.
Dysken 2014 measured cognition using the ADAS-Cog and
MMSE. At six to 48 months, participants taking vitamin E had
a smaller increase from baseline on the ADAS-Cog (an increase
in score representing worsening cognitive function) than partic-
ipants taking placebo, but the result was uncertain and unlikely
to be of clinical importance (completers: MD -1.81, 95% CI -
3.75 to 0.13, P = 0.07, 1 study, n = 272; moderate quality evi-
dence, downgraded due to imprecision because data were from a
single small study). There was no evidence of a difference between
groups in cognitive function measured with the MMSE (where a
decrease represents worsening function) (completers: MD 0.19,
95%CI -0.72 to 1.10, P = 0.68, 1 study, n = 273; moderate quality
evidence, downgraded due to imprecision).
Adverse events
Sano 1996 did not fully report adverse events. A total of 49 cate-
gories of adverse events were defined but the only results initially
reported were for three categories (dental events, falls and syncopal
episodes), in which there were significant differences between one
or more of the treatment groups and the placebo group. However,
once the authors adjusted for multiple comparisons, there were no
significant differences between groups.
Lloret 2009 did not report adverse events.We requested additional
information but this was not made available.
Dysken 2014 found no evidence of a difference between vitamin
E and placebo groups in the number of participants reporting any
adverse event or the number reporting at least one severe adverse
event. The numbers of participants reporting adverse events dur-
ing the study were 91/152 (59.9%) in the vitamin E group and
89/152 (58.6%) in the placebo group (RR 1.02, 95% CI 0.85
to 1.23, P = 0.82, 1 study, n = 304; moderate quality evidence,
downgraded due to imprecision). The number of participants re-
porting at least one severe adverse event were 82/152 (54.0%) in
the vitamin E group and 95/152 (62.5%) in the placebo group
over the 48-month trial (RR 0.86, 95% CI 0.71 to 1.05, P = 0.13,
1 study, n = 304; moderate quality evidence, downgraded due to
imprecision).
14Vitamin E for Alzheimer’s dementia and mild cognitive impairment (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Death
In Sano 1996, participants remained in the study until they
reached one of the four predefined end points, one of which was
death. In both vitamin E and placebo groups, 12% of participants
died. The authors also reported that treatment had no effect on
the cause of death.
Lloret 2009 did not report deaths. We requested additional infor-
mation but this was not made available.
Dysken 2014 found no evidence of a difference between vitamin
E and placebo groups in the number of deaths. There were 26/
152 (17.1%) deaths in the vitamin E group compared to 31/152
(20.4%) deaths in the placebo group over the 48-month trial (RR
0.84, 95% CI 0.52 to 1.34, P = 0.46, 1 study, n = 304; moderate
quality evidence, downgraded due to imprecision).
Secondary outcomes
Global measure of dementia severity and deterioration
None of the studies measured dementia severity and deterioration
(Dysken 2014; Lloret 2009; Sano 1996).
Behavioural disturbance
In Sano 1996, we were unable to extract the data for behavioural
disturbances despite these being measured as secondary outcomes
in the trial. Only the mean change scores to the time point where
a participant was last assessed were reported and participants had
been assessed over varying and unidentified time spans. SDs were
not reported.
Lloret 2009 did not measure behavioural disturbance.
Dysken 2014 found that neuropsychiatric symptoms increased
slightly more in the placebo group than in the vitamin E group
over six to 48 months using the NPI but the result was uncertain
and unlikely to be of clinical importance (completers: MD -1.47,
95%CI -4.26 to 1.32, P = 0.30, 1 study, n = 280; moderate quality
evidence, downgraded due to imprecision).
Mood
None of the studies measured mood (Dysken 2014; Lloret 2009;
Sano 1996).
Activities of daily living
In Sano 1996, we were unable to extract the data we had specified
for activities of daily living, despite these being measured as sec-
ondary outcomes in the trial. Only the mean change scores to the
time point where a participant was last assessed were reported and
participants had been assessed over varying and unidentified time
spans. SDs were not reported. The authors reported that there was
significantly less decline in activities of daily living, as measured
by the BDS and DS, in the vitamin E compared to the placebo
group, but no significant difference between groups on the BRSD.
Lloret 2009 measured activities of daily living using the BDS. The
authors did not report means and SDs, and therefore we were
unable to extract the data.
Dysken 2014 measured activities of daily living using the ADCS-
ADL. Participants receiving vitamin E showed less functional de-
cline on the ADCS-ADL than participants receiving placebo at
six to 48 months (completers: MD 3.15, 95% CI 0.07 to 6.23, P
= 0.04, 1 study, n = 280; moderate quality evidence, downgraded
due to imprecision).
Carer burden
None of the studies measured carer burden (Dysken 2014; Lloret
2009; Sano 1996).
Quality of life
None of the studies measured quality of life (Dysken 2014; Lloret
2009; Sano 1996).
Permanent physical disability
None of the studies measured permanent physical disability
(Dysken 2014; Lloret 2009; Sano 1996).
Institutionalisation
Sano 1996 reported that participants receiving vitamin E treat-
ment significantly delayed institutionalisation compared to par-
ticipants receiving placebo (RR 0.42, no CI reported; P = 0.003).
Neither Dysken 2014 nor Lloret 2009 measured institutionalisa-
tion.
Other study outcomes
Sano 1996 reported the number in each outcome group who
reached one of their primary end points (death, institutionalisa-
tion, change in severity of dementia to a CDR score of three or loss
of two basic activities of daily living) within two years; this was 45/
85 (53%) of participants in the vitamin E group and 58/84 (69%)
in the placebo group. Because the trial was limited in time, an
analysis comparing a count of events without taking into account
their timing is less precise than the survival analysis reported by
Sano 1996. Using Kaplan-Meier estimation and log-rank testing
in their primary analysis, Sano 1996 found no significant differ-
ence in survival time to one of the four end points between the vi-
tamin E and placebo groups (RR 0.70, no CI reported; P = 0.08).
However, the study groups differed in baseline MMSE scores and
these were correlated with clinical course. The vitamin E group
began with ameanMMSE of 11.3 (SD 5.7) and the placebo group
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with a mean MMSE of 13.3 (SD 4.9). When the analysis was re-
peated using the Cox proportional hazards model and controlling
for baseline MMSE, there emerged a significant difference favour-
ing vitamin E (RR 0.47, no CI reported; P = 0.001).
The primary outcomes reported by Lloret 2009 were the percent-
age change in performance from baseline to six months on the
BDS, Clock Drawing Test and MMSE, compared across respon-
ders (n = 9), non-responders (n = 10) and placebo-treated groups
(n = 14), where participants who showed a decrease in GSSG val-
ues of more than 10 nmol/mL of blood after six months of vita-
min E treatment were termed ’responders’ and participants who
did not were termed ’non-responders’. We found no evidence that
these groups had been defined before data collection. The authors
reported no significant difference between groups on the Clock
Drawing Test or BDS in an analysis of ’completers’ only. The
MMSE score increased in the responder group but decreased in
the placebo group and more so in the non-responders. There was a
significant difference between the two vitaminE-treated groups on
MMSE change score (P < 0.05). The responders did not differ sig-
nificantly from the placebo-treated group. The decline in MMSE
in the non-responders was significantly greater than in the placebo
group (P < 0.05). Lloret 2009 also reported a negative correlation
between change in MMSE score and change in blood levels of
GSSG from baseline to six months; that is, there was a greater
decline in cognitive performance in people with AD whose blood
GSSG levels stayed higher (reflecting higher oxidative stress).
Dysken 2014 reported that for functional decline, the mean treat-
ment effect of 3.15 units on the ADCS-ADL, favouring partici-
pants receiving vitamin E, translates into a clinically meaningful
delay in progression of 6.2 months (95% CI 5.4 to 7.4), based on
the rate of change in the control group.
Vitamin E for mild cognitive impairment
One study assessed vitaminE in people withMCI (Petersen 2005).
For a summary of findings for the treatment ofMCI, see Summary
of findings 2.
Primary outcomes
Development of, or time to development of, possible or
probable Alzheimer’s disease
Petersen 2005 found no evidence of an effect of vitamin E on the
numbers of participants with MCI who progressed to possible or
probable AD. As their primary outcome, Petersen 2005 reported
that 33/257 participants in the vitamin E group and 38/259 par-
ticipants in the placebo group progressed to possible or probable
AD in the first 12 months (RR 1.02, 95% CI 0.96 to 1.10, P =
0.05, 1 study, n = 516). By 36 months, 76/257 participants in the
vitamin E group and 73/259 in the placebo group had progressed
to AD (RR 1.03, 95% CI 0.79 to 1.35, P = 0.81, 1 study, n =
516). We considered this moderate quality evidence, downgraded
due to imprecision.
Cognitive function
Petersen 2005 reported no significant difference between those
receiving vitamin E and placebo on the change from baseline of
the MMSE, ADAS-Cog and modified ADAS-Cog. However, it
was difficult to tell how missing data had been handled and no
sample size was reported, so wewere unable to conduct an analysis.
Adverse events
Petersen 2005 did not fully report adverse events and therefore we
were unable to extract the data we required. The authors reported
the rates of 10 types of adverse events that occurred in at least
5% of participants in the vitamin E and at least two times in the
placebo group during the double-blind phase of the study. Diar-
rhoea and cataract extraction were the most frequently reported
adverse events in the vitamin E group. Neither of these adverse
events differed significantly in frequency between the vitamin E
and placebo groups (P > 0.05). Overall, 66/257 participants dis-
continued in the vitamin E group and 72/259 participants discon-
tinued treatment in the placebo group. Reasons were not given by
group, but in the study as a whole, most discontinuations resulted
from withdrawal of consent or adverse events.
Death
Petersen 2005 reported that five deaths occurred in each of the
vitamin E and placebo groups during the 36-month double-blind
phase (RR 1.01, 95% CI 0.30 to 3.44, P = 0.99, 1 study, n = 516;
moderate quality evidence, downgraded due to imprecision). All
deaths were deemed to be unrelated to treatment.
Secondary outcomes
Global measure of dementia severity and deterioration
Petersen 2005 reported no significant difference between those
receiving vitamin E and placebo on change scores of the CDR
Sum of Boxes or the Global Deterioration Scale. However, it was
difficult to tell how missing data had been handled and no sample
size was reported, so we were unable to conduct an analysis.
Behavioural disturbance
Petersen 2005 did not measure behavioural disturbance.
Mood
Petersen 2005 did not measure mood.
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Activities of daily living
Petersen 2005 reported no significant difference between those
receiving vitamin E and placebo on change scores of the ADCS
MCI-ADL. However, it was difficult to tell how missing data had
been handled and no sample size was reported, so we were unable
to conduct an analysis.
Carer burden
Petersen 2005 did not measure carer burden.
Quality of life
Petersen 2005 did not measure quality of life.
Permanent physical disability
Petersen 2005 did not measure permanent physical disability.
Institutionalisation
Petersen 2005 did not measure institutionalisation.
Other study outcomes
Petersen 2005 also created standardised z-scores of individual cog-
nitive domains (memory, executive, language, visuospatial and
overall cognition) and reported the change from baseline for each.
There were few significant differences in cognitive function change
scores between the vitamin E and placebo groups. Those that were
seen (in the executive, language and overall cognitive scores) were
confined to the first 18 months of the study. On average, executive
function improved in both groups at six months, but the improve-
ment was significantly greater in the vitamin E group compared
to the placebo group (P < 0.05). Change in language scores signif-
icantly favoured vitamin E at six months (P < 0.05), 12 months
(P < 0.05) and 18 months (P < 0.05). Overall cognitive changes
scores significantly favoured vitamin E at six months (P < 0.01),
with an improvement in cognition in the vitamin E group and a
decline in cognition in the placebo group. There were no differ-
ences between groups in the second 18 months of the study (18
to 36 months).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Vitamin E (capsules 2000 IU/day in 2 divided doses) compared to placebo for people with mild cognitive impairment
Patient or population: people with mild cognit ive impairment
Settings: US and Canada
Intervention: vitamin E (capsules 2000 IU/ day in 2 divided doses)
Comparison: placeb
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Vitamin E (capsules
2000 IU/day in 2 di-
vided doses)
Progression to
Alzheimer’s disease
Number of people pro-
gressing to AD
Follow-up: 36 months
284 per 1000 293 per 1000
(224 to 383)
RR 1.03
(0.79 to 1.35)
516
(1 study)
⊕⊕⊕©
Moderate1
-
Cognitive function
Mean change f rom
baseline of ADAS-Cog
Scale f rom: 0 to 70
Follow-up: 36 months
Not possible to extract data for analysis. - Not possible to extract
data for analysis.
Unable to evaluate qual-
ity of evidence.
Uncertainty about how
missing data were han-
dled. Study reports
no signif icant dif f er-
ence between interven-
t ion and control groups
Adverse events
Number of part icipants
report ing ≥ 1 serious
adverse event.
Follow-up: 36 months
Not possible to extract data for analysis. - 516
(1 study)
Unable to evaluate qual-
ity of evidence.
Overall adverse event
rates not reported.
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Death
Number of deaths over
36 months
Follow-up: 36 months
19 per 1000 19 per 1000
(6 to 66)
RR 1.01
(0.3 to 3.44)
516
(1 study)
⊕⊕⊕©
Moderate1
-
Activities of daily living
Mean change f rom
baseline using the
ADCS
Mild Cognit ive Impair-
ment Act ivit ies of Daily
Living
Scale f rom: 0 to 53
Follow-up: 36 months
Not possible to extract data for analysis. - Not possible to extract
data for analysis.
Unable to evaluate qual-
ity of evidence.
Uncertainty about how
missing data were han-
dled. Study reports
no signif icant dif f er-
ence between interven-
t ion and control groups
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
ADAS-Cog: Alzheimer Disease Assessment Scale - Cognit ive Subscale; ADCS-ADL: Alzheimer’s Disease Cooperat ive Study/ Act ivit ies of Daily Living Inventory;CI: conf idence
interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Quality downgraded one level due to imprecision. Evidence f rom a single study of modest size. This was supported by
dichotomous data not reaching the opt imal information size criterion (assuming α of 0.05, and β of 0.2) (Guyatt 2011).
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D I S C U S S I O N
Summary of main results
Four studies met the inclusion criteria and were selected for this
review. To our knowledge there are currently no relevant ongo-
ing trials. Three studies assessed the efficacy of vitamin E in peo-
ple with AD (Dysken 2014; Lloret 2009; Sano 1996), while one
study assessed vitamin E in people with MCI (Petersen 2005). A
significant limitation of this review is that synthesis of data from
the AD studies was not possible owing to different outcome mea-
sures, heterogeneity in designs and the inability to access relevant
data sets from authors’ reports. The Lloret 2009 study used a dose
of vitamin E of 800 IU/day in the intervention group while the
studies by Dysken 2014, Sano 1996, and Petersen 2005 used a
dose of vitamin E of 2000 IU/day. Participants in the Sano 1996
study withdrew from the study once they reached a series of clin-
ical end points. We could use data only from the Dysken 2014
and Petersen 2005 studies.
Vitamin E for dementia due to Alzheimer’s disease
We found no evidence from the one study from which we could
extract data that vitamin E was efficacious in improving cognitive
outcomes in dementia due to AD (Dysken 2014). We could not
extract data from Sano 1996 or Lloret 2009.
For our other primary outcomes, adverse events and deaths, there
was no evidence that participants with AD receiving vitamin E
were more at risk than participants receiving placebo (Dysken
2014; Sano 1996). From this review, we were unable to comment
on the safety or tolerability of higher doses of alpha-tocopherol
or of other tocopherol and tocotrienol forms. In what appeared
to be a post hoc analysis, Lloret 2009 reported that the subgroup
of participants with AD who responded to vitamin E with a re-
duction in measures of oxidative stress had similar cognitive out-
comes to participants taking placebo, while participants showing
no reduction in oxidative stress measures in response to vitamin
E had significantly poorer cognitive outcomes. This was very low
quality evidence due to the post hoc definition of response, the
small sample size and other significantmethodological limitations,
but the apparent accelerated decline in cognitive abilities in those
participants in whom vitamin E did not reduce oxidative stress
measures suggests a need for caution in future trials.
Among our secondary outcomes, we could extract data from
Dysken 2014 on behavioural disturbance, which did not differ
between groups, and on performance of activities of daily living,
which declined less over a mean follow-up of 2.27 years in the
vitamin E than in the placebo group. We were unable to extract
any data on our secondary outcomes of global dementia severity,
mood, carer burden, quality of life, physical disability or institu-
tionalisation.
Vitamin E for mild cognitive impairment
Petersen 2005 was the only study identified that investigated the
effects of vitamin E on the progression from MCI to AD. We
found no evidence that vitamin E treatment affected the risk of
progression to AD over 36 months compared to placebo. The
evidence presented by Petersen 2005 also suggests that vitamin E
was not efficacious in improving cognitive outcomes in MCI.
There was no evidence that vitamin E treatment increased the risk
of death, and while we were unable to extract data for adverse
events, the data presented by the authors indicated that the risk
of adverse events also did not differ between treatment groups. As
with the AD sample, we were unable to comment on the safety or
tolerability of higher doses of alpha-tocopherol or of other toco-
pherol and tocotrienol forms in an MCI population.
Among our secondary outcomes, we were unable to analyse data
on activities of daily living and global severity because sample
sizes were not clearly reported. However, the data presented by
the authors showed no evidence that either outcome benefited
from vitamin E treatment compared to placebo. The study did not
measure mood, carer burden, quality of life, physical disability or
institutionalisation, so we could not draw any conclusions about
the effect of vitamin E on these outcomes in an MCI population.
Overall completeness and applicability of
evidence
The review was based on a small number of RCTs that were het-
erogeneous in design thus preventing a meta-analysis. Notably, no
two studies included in this review had the same primary outcome,
while only a single study investigated vitamin E treatment in a
MCI population (Petersen 2005).
Quality of the evidence
Using the GRADE approach, we rated the overall quality of evi-
dence for all outcomes to be moderate. We considered the studies
from which we extracted data to be at low to unclear risk of bias.
However, we downgraded all quality judgements one level due to
imprecision because all data came from single modest-sized studies
and we therefore considered it likely that further research could
have an impact on the effect estimates.
See Summary of findings for the main comparison and Summary
of findings 2.
Potential biases in the review process
Tominimise the possibility of bias, we tried to locate all RCTs by a
broad and comprehensive search strategy in a number of databases.
We sought additional information from the authors of one study
but were unable to obtain it (Lloret 2009). The review was limited
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by our inability to obtain or extract the data we needed from two
of the included studies.
Agreements and disagreements with other
studies or reviews
Habitual intake of dietary antioxidants has not consistently been
found to improve cognitive performance or reduce the risk of de-
mentia (Crichton 2013). While vitamin E assessed in epidemio-
logical studies in relation to cognition has consisted of the various
naturally occurring forms (Engelhart 2002; Morris 2002; Morris
2005), the relationship between vitamin E and cognition is un-
clear. In the present systematic review, there was no evidence that
vitamin E improved either cognition or risk of developing AD.
Morris 2005 suggested that the combined intake of tocopherols
is likely to be more important than alpha-tocopherol alone. This
is further supported by Mangialasche 2010 who studied the rela-
tionship between cognitive impairment and the eight individual
forms of vitamin E and concluded that any potential neuroprotec-
tive effect for vitamin E may result from interaction of the various
forms.
It has been previously reported that vitamin E, especially in the
large doses used in the included studies, may be associated with
potentially significant adverse effects and even an increased rate
of all-cause mortality (Miller 2005). High doses of alpha-toco-
pherol also have the potential to induce enzymes involved in drug
metabolism with an associated risk of serious interactions with
some concomitant medication (Brigelius-Flohé 2007). However,
this review found no evidence that vitamin E treatment signif-
icantly affected the number of serious adverse events or deaths,
although the relatively short study lengths and small sample sizes
mean that no strong conclusions about the safety of vitamin E can
be drawn from these data.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review found little evidence for the efficacy of vitamin E (al-
pha-tocopherol) in the treatment of Alzheimer’s disease (AD). We
found no evidence that it affects cognition, although there was
moderate quality evidence from one study that it may slow func-
tional decline, changing our conclusions from the previous up-
date. However, based upon the quality of evidence, it is likely that
further trials could have an impact on this finding. We consider it
important to inform patients, carers and professionals about the
lack of evidence for efficacy and the potential hazards of using vi-
tamin E in AD. It should be noted that the conclusions are based
only on the alpha-tocopherol formulation of vitamin E, and hence
no comment can be made on the efficacy of other preparations.
Implications for research
Vitamin E is a powerful antioxidant and plays an important role in
protecting cells against the harmful effects of free radicals. There is
sufficient evidence from laboratory and animal studies to consider
it of potential interest as a treatment for people with AD. Overall,
however, there continues to be a paucity of randomised controlled
trials investigating the efficacy of vitamin E in AD. The findings
fromDysken 2014 are interesting and indicate that vitamin Emay
slow functional decline in AD. Further research is now warranted
to assess this further. Additional research is also needed to explore
the effects of vitamin E treatment on other clinically relevant out-
comes, such as quality of life, which was not assessed in any of the
trials identified in this review. This review is a good example of the
need to have more uniform outcomes across trials, with a focus on
identifying outcomes that are meaningful to patients and carers.
Lloret 2009 was a small study, but interesting as it showed a harm-
ful effect on cognition in those participants whose oxidative stress
markers did not respond to vitamin E intake. However, the size
and high number of dropouts in this study limits the conclusions
that can be drawn. Other studies included in this review did not
measure antioxidant or nutritional levels prior to randomisation.
The assessment of oxidative stressmarkers in future trials should be
considered in order to understand further the oxidant-antioxidant
balance in relation to vitamin E effects in AD. In addition, the
exclusive use of the alpha-tocopherol form of vitamin E in clinical
trials has been criticised. Future studies should investigate other
tocopherol and tocotrienol forms. We will consider investigating
subgroups by vitamin E formulation and oxidative stress response
in future updates of this review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dysken 2014
Methods Design: multicentre, randomised, double-blind, placebo-controlled trial
Duration: 6 months to 4 years
Participants Diagnosis (including criteria used): possible or probable AD (NINCDS-ADRDA)
Number of participants: 613 total randomised (completers: 140 in vitamin E group,
140 in placebo group, 142 in memantine group, 139 in the vitamin E + memantine
group)
Age: 53 to 96 years, mean age 78.8 years
Gender: 97% men
Cognitive status (e.g. MMSE): 21
Ethnicity: 86% white
Inclusion criteria: diagnosis of possible or probable AD (NINCDS-ADRDA); presence
of a carer (friend or relative); informed consent; MMSE 12 to 26; administration of
maintenance dosage of acetylcholinesterase inhibitors for at least 4 weeks; agreement not
to take vitamin E/memantine outside the study
Exclusion criteria: non-Alzheimer’s primary dementia; current major depression, delir-
ium, alcohol or psychoactive substance abuse or dependency; schizophrenia, or delu-
sional disorder as defined by DSM-IV; presence of any uncontrolled systemic illness that
would interfere with participation in the study or life expectancy of < 1 year; pregnant or
intention to become pregnant; enrolment in another interventional clinical trial; current
prescription with more than one acetylcholinesterase inhibitor; current prescription for
warfarin; use of vitamin E supplements in the past 2 weeks; use of memantine in the
past 4 weeks or known intolerance; estimated creatinine clearance < 5 mL/minute; use
of amantadine in the past 2 weeks
Interventions Treatment 1: vitamin E (2000 IU total daily dose divided into 2 doses)
Treatment 2: memantine (20 mg/day)
Treatment 3: vitamin E + memantine
Treatment 4: placebo
Outcomes ADCS-ADL (months 0, 6, 12, 18, 24, 30, 36, 42, 48)
MMSE (months 0, 6, 12, 18, 24, 30, 36, 42, 48)
ADAS-Cog (months 0, 6, 12, 18, 24, 30, 36, 42, 48)
DS (months 0, 6, 12, 18, 24, 30, 36, 42, 48)
NPI (months 0, 6, 12, 18, 24, 30, 36, 42, 48)
Caregiver Activity Survey (months 0, 6, 12, 18, 24, 30, 36, 42, 48)
Adverse events
Notes On average, carers reported that vitamin E was taken on 65% of the days
Risk of bias
Bias Authors’ judgement Support for judgement
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Dysken 2014 (Continued)
Random sequence generation (selection
bias)
Low risk Participants randomised centrally using “.
..a random permuted block design of ran-
domly varying sizes between 4 and 12.”
Allocation concealment (selection bias) Low risk “…participants were randomized centrally
into one of the four treatment groups…”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The patient, caregivers, and all site inves-
tigators were blinded to the treatment as-
signment.” Participants received “matching
placebos for vitamin E were hard-gelatin,
liquid-filled capsules containing soybean
oil.” The authors did not describe whether
blinding was successful
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “The patient, caregivers, and all site inves-
tigators were blinded to the treatment as-
signment.” The authors did not describe
how blinding was maintained and whether
it was successful
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete outcome data was comparable
between the vitamin E group and placebo
group (12participants excluded in each due
to a lack of follow-up data)
Selective reporting (reporting bias) Low risk Study protocol was published, which in-
cluded the primary and secondary out-
comes as included in the main paper
Other bias Low risk No other sources of bias noted.
Lloret 2009
Methods Design: randomised, placebo-controlled, double-blind study
Duration: 6 months
Participants Country: Spain
Number of centres: 1
Diagnosis: probable AD according to NINCDS-ADRDA
Number of participants: 57 participants total randomised (completers: 19 in vitamin
E group, 14 in placebo group), 18 healthy controls
Age: not described
Gender: not described
Ethnicity: not described
Cognitive status: severity of participants based on the Geriatric Dementia Scale - mild
(n = 25), moderate (n = 26) and severe (n = 6)
Inclusion criteria: not described
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Lloret 2009 (Continued)
Exclusion criteria: people taking antioxidant supplements or any medication other than
cholinesterase inhibitors
Interventions Treatment 1: vitamin E 800 IU/day
Treatment 2: placebo daily
Outcomes Clock Drawing Test (months 0 and 6)
BDS (months 0 and 6)
MMSE (months 0 and 6)
Blood total glutathione levels and oxidised glutathione (months 0 and 6)
Plasma malondialdehyde (months 0 and 6)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was performed using a
randomized list of numbers.”
Allocation concealment (selection bias) Unclear risk No reference made to how allocation con-
cealment was ensured.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study described as ’double blind’ but au-
thors did not describe how blinding was
maintained and whether it was successful.
It is unclear whether the placebo was iden-
tical in appearance to the vitamin E treat-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study described as ’double blind’ but au-
thors did not describe how blinding was
maintained and whether it was successful
Incomplete outcome data (attrition bias)
All outcomes
High risk 24/57 AD participants did not complete
the research. “Of the patients who finished
the study, 14 had been treated with placebo
and 19 with vitamin E.” The reasons for
participant dropout were not described
Selective reporting (reporting bias) Unclear risk Outcomes reported, though the level of de-
tail lacking. For example, means and SDs
not described
Other bias Low risk No evidence of other bias.
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Petersen 2005
Methods Design: randomised, placebo-controlled, double-blind study
Duration: 36 months
Participants Country: US and Canada
Number of centres: 69
Diagnosis: amnestic type of MCI
Number of participants: 769 total randomised (ITT: 257 in vitamin E group, 259 in
placebo group, 253 in donepezil group)
Gender: 46% women
Age: 55 to 90 years, mean 73 years
Cognitive status: MMSE 24 to 30, mean MMSE 27.3
Inclusion criteria: amnestic MCI of a degenerative nature, impaired memory, a Logical
Memory delayed-recall score approximately 1.5 to 2 SD below an education adjusted-
norm, a CDR of 0.5, MMSE score 24 to 30, and 55 to 90 years of age. adequate vision
and hearing for neuropsychological testing, normal vitamin B12 and thyroid function
studies and non-reactive RPR. ECG normal or no clinical significant abnormalities.
Study informant available
Exclusion criteria: significant cerebral vascular disease, modified Hachinski > 4; Hamil-
ton Depression Rating Scale > 12; central nervous system infarct, infection or focal le-
sions of clinical significance on CT or MRI scan. Medical diseases or psychiatric disor-
ders that could interfere with study participation. Pregnant, lactating or of child-bearing
potential; taking vitamin supplements, other supplements or multivitamin. Restriction
on concomitant medication usage, including those with significant cholinergic or anti-
cholinergic effects or potential adverse effects on cognition
Interventions Treatment 1: vitamin E group (2000 IU total daily dose divided into 2 doses, placebo
donepezil and a multivitamin daily)
Treatment 2: donepezil group (donepezil 10 mg, placebo vitamin E and a multivitamin
daily)
Treatment 3: placebo group (placebo vitamin E, placebo donepezil and a multivitamin
daily)
Note: the initial dose of vitamin E was 1000 IU/day, and the dose was increased to 2000
IU (1000 IU twice daily) after 6 weeks. The multivitamin contained vitamin E 15 IU
Outcomes Time to possible or probable development of AD
MMSE (months 0, 6, 12, 18, 24, 30, 36)
ADAS-Cog (months 0, 6, 12, 18, 24, 30, 36)
Global CDR (months 0, 6, 12, 18, 24, 30, 36)
ADCS Mild Cognitive Impairment Activities of Daily Living Scale (months 0, 6, 12,
18, 24, 30, 36)
GDS (months 0, 6, 12, 18, 24, 30, 36)
Neuropsychological battery including; New York University paragraph-recall test, the
Symbol Digit Modalities Test, the category-fluency test, a number-cancellation test, the
Boston Naming Test, the digits-backward test, the Clock Drawing Test, and a maze-
tracing task (months 0, 6, 12, 18, 24, 30, 36)
Adverse events
Notes -
Risk of bias
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Petersen 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomly assigned to treat-
ment groups. The authors used “…an
adaptive allocation scheme for the treat-
ment assignment, with the MMSE score,
age, and APOE e4 status as balancing co-
variates.”
Allocation concealment (selection bias) Unclear risk No reference made to the method in which
allocation concealment was ensured
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study described as ’double blind’ but au-
thors did not describe how blinding was
maintained and whether it was successful.
Unclear whether the placebo was identical
in appearance to the vitamin E treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study described as ’double blind’ but au-
thors did not describe how blinding was
maintained and whether it was successful
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “The primary analysis was conducted ac-
cording to the intention-to-treat principle.
”During the double-blindphase, 72partic-
ipants discontinued in the vitaminE group,
and 66 in placebo group. Sensitivity anal-
yses suggested no impact of dropouts on
the results regarding vitamin E and placebo
groups. 76 participants in the vitamin E
group and 73 in the placebo group de-
veloped AD and switched to open label
donepezil. It is not clear how subsequent
data from these participants was handled
Selective reporting (reporting bias) Low risk All outcomes reported in accordance with
the methods section
Other bias Low risk No evidence of other bias.
Sano 1996
Methods Design: randomised, placebo-controlled, double-blind study
Duration: 24 months
Participants Country: US
Multicentre: 23 sites
Diagnosis: probable AD according to NINCDS-ADRDA
Number of participants: 341 total randomised (completers: 85 in vitamin E group, 84
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Sano 1996 (Continued)
in placebo group, 87 in selegiline group, 85 in selegiline + vitamin E group)
Gender: 65% women
Age: mean 73 years
Ethnicity: not described
Cognitive status: mean MMSE 12.6
Inclusion criteria: diagnosis of probable AD, aged ≥ 45 years, fluent in English or
Spanish, CDR score 2, modified Hachinski score 4, supervised by a responsible carer
Exclusion criteria: other central nervous system or psychiatric diagnosis; achieving end
point on any primary outcome measure at time of entry; participation in any other in-
vestigational drug study or treatment with a psychoactive medication within 2 months
of initiation of this trial; treatment with antiparkinsonian medications; recent initiated
treatment for a non-psychiatric condition with an agent to have psychoactive properties
(e.g. beta-blockers, calcium channel blockers). Entry permitted if medication and dose
had been stable for 3 months prior to entry into the protocol; antilipaemic drugs specif-
ically contradicted with selegiline (i.e. cholestyramine or colestipol) within 2 weeks of
enrolment; some narcotics: demerol has been reported to interact with selegiline; ancil-
lary vitamin E (alpha tocopherol) other than the 30 IU to 32 IU included in a standard
multivitamin
Interventions Treatment 1: placebo
Treatment 2: vitamin E (2000 IU total daily dose divided into 2 doses)
Treatment 3: selegiline (10 mg total daily dose divided into 2 doses)
Treatment 4: vitamin E (2000 IU total daily dose divided into 2 doses) + selegiline (10
mg total daily dose divided into 2 doses)
Outcomes Delay in any of 4 end points: death; institutionalisation; severity of dementia; loss of
ADL
ADAS-Cog (1 month after enrolment and at 3-month intervals)
MMSE (1 month after enrolment and at 3-month intervals)
BDS (1 month after enrolment and at 3-month intervals)
DS (1 month after enrolment and at 3-month intervals)
BRSD (1 month after enrolment and at 3-month intervals)
Adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participantswere “...randomly assigned (af-
ter stratification according to center with
the use of a permuted-block procedure)...”
to receive vitamin E or placebo
Allocation concealment (selection bias) Unclear risk Method in which allocation concealment
was ensured was not reported
35Vitamin E for Alzheimer’s dementia and mild cognitive impairment (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sano 1996 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study described as ’double blind’ but au-
thors did not describe how blinding was
maintained and whether it was successful.
Unclear whether the placebo and vitamin
E treatment capsules were visually identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study described as ’double blind’ but au-
thors did not describe how blinding was
maintained and whether it was successful
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition was only able to be reported up
until the point a participant reached 1 of
the primary end points of the study. Loss to
follow-up was defined as those who did not
reach an end point and did not complete
the study: 6/84 for the placebo group and
8/85 for the vitamin E group. The reasons
for withdrawal were not described in each
treatment group
Selective reporting (reporting bias) Unclear risk All outcome measures were reported as per
the protocol paper. No SDs reported for
change scores
Other bias Low risk No evidence of other bias.
AD: Alzheimer’s dementia; ADAS-Cog: Alzheimer’s Disease Assessment Scale - Cognitive subsection; ADCS: Alzheimer’s Disease
Cooperative Study; ADL: activities of daily living; APoE: apolipoprotein E; BDS: Blessed Dementia Scale; BRSD: Behavior Rating
Scale for Dementia; CDR: Clinical Dementia Rating; CT: computer tomography; DS: Dependence Scale; DSM-IV: Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition; ECG: electrocardiography; GDS: Global Deterioration Scale; ITT:
intention to treat;MCI: mild cognitive impairment; MMSE:Mini-Mental State Examination; MRI: magnetic resonance imaging; n:
number of participants; NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association; NPI: Neuropsychiatric Inventory; RPR: rapid plasmin reagin; SD: standard
deviation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alavi 2013 Not suitable placebo
Alavi 2014 Control group did not receive a suitable placebo.
Alzoubi 2012 Sample population did not have a diagnosis of MCI or AD.
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(Continued)
Anand 2011 Sample population did not have a diagnosis of MCI or AD.
Anonymous 2014 Newsletter
Apostolova 2013 Not an RCT
Arlt 2012 Not an RCT
Biesalski 2010 Review
Bittner 2009 Retrospective design
Brewer 2010 Review
Carlsson 2002 Sample population did not have a diagnosis of MCI or AD.
Chan 2008-2009 Used a nutriceutical formulation and there was no placebo.
Chan 2010 Used a nutriceutical formulation. Placebo was just inert ingredients
Chapman 2014 Editorial
Clarke 2003 Vitamin E was used in conjunction with vitamin C.
It examined the association of cognitive impairment with platelet activation and reactive oxygen species
and total homocysteine levels
Corbett 2014 Commentary
Cornelli 2010 Used a nutriceutical formulation, not vitamin E separately.
de Oliveira 2012 In vitro study
Dunham 2013 Review
Dysken 2009 No vitamin E intervention, just a questionnaire
Evans 2014 Editorial
Galasko 2012 Not suitable placebo
Geldmacher 2011 Pioglitazone was the primary intervention. Placebo was administered alongside vitamin E
Gopalan 2014 Sample population did not have a diagnosis of MCI or AD.
Grodstein 2013 Sample population did not have a diagnosis of MCI or AD.
Guan 2012 No relevant outcome measures
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(Continued)
Gutierrez 2009 Sample population did not have a diagnosis of MCI or AD.
Han 2011 Review
Hermann 2014 Newsletter
Jae 2006 Vitamin E intervention given to healthy older women.
Joshi 2012 Review
Jyvakorpi 2012 Not an RCT
Kamat 2008 Literature review about antioxidants
Kesse-Guyot 2011a Sample population did not have a diagnosis of MCI or AD.
Kesse-Guyot 2011b Sample population did not have a diagnosis of MCI or AD.
Kryscio 2013a Sample population did not have a diagnosis of MCI or AD.
Kryscio 2013b Sample population did not have a diagnosis of MCI or AD.
Lee 2010 Literature review about antioxidants
Lehtisalo 2013 No vitamin E intervention group
Lehtisalo 2014 No vitamin E intervention group
Lewis 2014 Sample population did not have a diagnosis of MCI or AD.
Li 2015 No placebo group
Lott 2011 Sample population had a diagnosis of Down’s syndrome and dementia
Lu 2009 Focus of intervention was towards depressed vs non-depressed MCI population
MacPherson 2012 Sample population did not have a diagnosis of MCI or AD.
Mecocci 2012 Review
Mishra 2012 Survey
Morris 2012a Review
Morris 2012b Review
Muss 2015 Sample population did not have a diagnosis of MCI or AD.
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(Continued)
Naeini 2014 No co-administration of other compounds to controls
Onofrj 2002 Vitamin E compared to donepezil not placebo.
Pavlik 2009 Retrospective in nature. No controls or placebo group
Podea 2012 Not an RCT
Polidori 2012 Review
Pribis 2012 Did not use vitamin E as an intervention.
Péneau 2011 Not a randomised double-blinded study; investigated the intake of fruits and vegetables
Remington 2009 Used a nutriceutical formulation and the placebo was inert.
Remington 2015 Used a nutriceutical formulation.
Rijpma 2014a Systematic review
Rijpma 2014b Used a nutriceutical formulation.
Satalich 2014 Secondary analysis (modelling) of intervention data
Schmitt 2009 Used a healthy population.
Schneider 2009 Same data as Petersen 2005
Shea 2013 Used a nutriceutical formulation, not vitamin E separately.
Srour 2013 Vitamin C taken by treatment arm but not controls, no relevant outcomes
Stough 2012 Sample population did not have a diagnosis of MCI or AD.
Suominen 2013 Vitamin E not administered
Takahashi 2009 Case study, no placebo and no controls
Usoro 2010 Review
Vinyoles-Bargallo 2010 Not an original paper, just a personal comment
von Arnim 2013 Vitamin E not administered
Whitehair 2010 Same data as Petersen 2005
Zanotta 2014 Not an RCT
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AD: Alzheimer’s dementia; MCI: mild cognitive impairment; RCT: randomised controlled trial.
Characteristics of ongoing studies [ordered by year of study]
Gopal 2005
Trial name or title Effects of Vitamin E on Cognition and Measures of Activities of Daily Living in Patients with Moderately
Severe Alzheimer’s Disease
Methods Unknown
Participants People with moderately severe Alzheimer’s disease
Interventions Vitamin E 500 mg twice daily with cholinesterase inhibitors
Outcomes Changes in cognition and activities of daily living
Starting date 1 November 2002
Contact information Dr Vishnu Gopal; Argyll House, 9 Williamson Road, Nether Edge, Sheffield S11 9AR; tel: (+44) 114
2718656; email: vgopal@doctors.org.uk
Notes Study topic and author searched online, no evidence of trial or published data. Author no longer at contact
address, emailed for an update but no response
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D A T A A N D A N A L Y S E S
Comparison 1. Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer’s
disease
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Alzheimer’s Disease Assessment
Scale - Cognitive subscale
(ADAS-Cog) (least square (LS)
mean change from baseline at 6
to 48 months): completers
1 272 Mean Difference (IV, Random, 95% CI) -1.81 [-3.75, 0.13]
2 Alzheimer’s Disease Cooperative
Study/Activities of Daily Living
(ADCS-ADL) (LS mean
change from baseline at 6 to 48
months): completers
1 280 Mean Difference (IV, Fixed, 95% CI) 3.15 [0.07, 6.23]
3 Deaths (number of deaths over
48 months)
1 304 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.52, 1.34]
4 Serious adverse events (number
of participants reporting ≥ 1
serious adverse event over 48
months)
1 304 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.71, 1.05]
5 Neuropsychiatric Inventory
(NPI) (LS mean change from
baseline at 6 to 48 months):
completers
1 280 Mean Difference (IV, Fixed, 95% CI) -1.47 [-4.26, 1.32]
6 Mini-Mental State Examination
(MMSE) (LS mean change
from baseline at 6 to 48
months): completers
1 273 Mean Difference (IV, Fixed, 95% CI) 0.19 [-0.72, 1.10]
7 Adverse events (number of
participants reporting ≥ 1
adverse event over 48 months)
1 304 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.85, 1.23]
Comparison 2. Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with mild
cognitive impairment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Progression to Alzheimer’s
disease (AD) (number of
people progressing to AD by
36 months)
1 516 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.79, 1.35]
41Vitamin E for Alzheimer’s dementia and mild cognitive impairment (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2 Deaths (number of deaths over
36 months)
1 516 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.30, 3.44]
Analysis 1.1. Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people
with Alzheimer’s disease, Outcome 1 Alzheimer’s Disease Assessment Scale - Cognitive subscale (ADAS-Cog)
(least square (LS) mean change from baseline at 6 to 48 months): completers.
Review: Vitamin E for Alzheimer’s dementia and mild cognitive impairment
Comparison: 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer’s disease
Outcome: 1 Alzheimer’s Disease Assessment Scale - Cognitive subscale (ADAS-Cog) (least square (LS) mean change from baseline at 6 to 48 months): completers
Study or subgroup VItamin E Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Dysken 2014 135 5.97 (8.13) 137 7.78 (8.19) 100.0 % -1.81 [ -3.75, 0.13 ]
Total (95% CI) 135 137 100.0 % -1.81 [ -3.75, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours vitamin E Favours placebo
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Analysis 1.2. Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people
with Alzheimer’s disease, Outcome 2 Alzheimer’s Disease Cooperative Study/Activities of Daily Living
(ADCS-ADL) (LS mean change from baseline at 6 to 48 months): completers.
Review: Vitamin E for Alzheimer’s dementia and mild cognitive impairment
Comparison: 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer’s disease
Outcome: 2 Alzheimer’s Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) (LS mean change from baseline at 6 to 48 months): completers
Study or subgroup Vitamin E Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dysken 2014 140 -13.81 (13.13) 140 -16.96 (13.13) 100.0 % 3.15 [ 0.07, 6.23 ]
Total (95% CI) 140 140 100.0 % 3.15 [ 0.07, 6.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.045)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours placebo Favours vitamin E
Analysis 1.3. Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people
with Alzheimer’s disease, Outcome 3 Deaths (number of deaths over 48 months).
Review: Vitamin E for Alzheimer’s dementia and mild cognitive impairment
Comparison: 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer’s disease
Outcome: 3 Deaths (number of deaths over 48 months)
Study or subgroup VItamin E Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dysken 2014 26/152 31/152 100.0 % 0.84 [ 0.52, 1.34 ]
Total (95% CI) 152 152 100.0 % 0.84 [ 0.52, 1.34 ]
Total events: 26 (VItamin E), 31 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours vitamin E Favours placebo
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Analysis 1.4. Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people
with Alzheimer’s disease, Outcome 4 Serious adverse events (number of participants reporting ≥ 1 serious
adverse event over 48 months).
Review: Vitamin E for Alzheimer’s dementia and mild cognitive impairment
Comparison: 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer’s disease
Outcome: 4 Serious adverse events (number of participants reporting≥ 1 serious adverse event over 48 months)
Study or subgroup VItamin E Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dysken 2014 82/152 95/152 100.0 % 0.86 [ 0.71, 1.05 ]
Total (95% CI) 152 152 100.0 % 0.86 [ 0.71, 1.05 ]
Total events: 82 (VItamin E), 95 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours vitamin E Favours placebo
Analysis 1.5. Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people
with Alzheimer’s disease, Outcome 5 Neuropsychiatric Inventory (NPI) (LS mean change from baseline at 6 to
48 months): completers.
Review: Vitamin E for Alzheimer’s dementia and mild cognitive impairment
Comparison: 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer’s disease
Outcome: 5 Neuropsychiatric Inventory (NPI) (LS mean change from baseline at 6 to 48 months): completers
Study or subgroup Vitamin E Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dysken 2014 140 0.79 (11.83) 140 2.26 (11.95) 100.0 % -1.47 [ -4.26, 1.32 ]
Total (95% CI) 140 140 100.0 % -1.47 [ -4.26, 1.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours vitamin E Favours placebo
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Analysis 1.6. Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people
with Alzheimer’s disease, Outcome 6 Mini-Mental State Examination (MMSE) (LS mean change from baseline
at 6 to 48 months): completers.
Review: Vitamin E for Alzheimer’s dementia and mild cognitive impairment
Comparison: 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer’s disease
Outcome: 6 Mini-Mental State Examination (MMSE) (LS mean change from baseline at 6 to 48 months): completers
Study or subgroup Vitamin E Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dysken 2014 136 -2.97 (3.85) 137 -3.16 (3.86) 100.0 % 0.19 [ -0.72, 1.10 ]
Total (95% CI) 136 137 100.0 % 0.19 [ -0.72, 1.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours placebo Favours vitamin E
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Analysis 1.7. Comparison 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people
with Alzheimer’s disease, Outcome 7 Adverse events (number of participants reporting ≥ 1 adverse event
over 48 months).
Review: Vitamin E for Alzheimer’s dementia and mild cognitive impairment
Comparison: 1 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with Alzheimer’s disease
Outcome: 7 Adverse events (number of participants reporting≥ 1 adverse event over 48 months)
Study or subgroup VItamin E Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dysken 2014 91/152 89/152 100.0 % 1.02 [ 0.85, 1.23 ]
Total (95% CI) 152 152 100.0 % 1.02 [ 0.85, 1.23 ]
Total events: 91 (VItamin E), 89 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours vitamin E Favours placebo
Analysis 2.1. Comparison 2 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people
with mild cognitive impairment, Outcome 1 Progression to Alzheimer’s disease (AD) (number of people
progressing to AD by 36 months).
Review: Vitamin E for Alzheimer’s dementia and mild cognitive impairment
Comparison: 2 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with mild cognitive impairment
Outcome: 1 Progression to Alzheimer’s disease (AD) (number of people progressing to AD by 36 months)
Study or subgroup Vitamin E Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Petersen 2005 76/259 73/257 100.0 % 1.03 [ 0.79, 1.35 ]
Total (95% CI) 259 257 100.0 % 1.03 [ 0.79, 1.35 ]
Total events: 76 (Vitamin E), 73 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours vitamin E Favours placebo
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Analysis 2.2. Comparison 2 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people
with mild cognitive impairment, Outcome 2 Deaths (number of deaths over 36 months).
Review: Vitamin E for Alzheimer’s dementia and mild cognitive impairment
Comparison: 2 Vitamin E (capsules 2000 IU/day in two divided doses) versus placebo in people with mild cognitive impairment
Outcome: 2 Deaths (number of deaths over 36 months)
Study or subgroup Vitamin E Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Petersen 2005 5/257 5/259 100.0 % 1.01 [ 0.30, 3.44 ]
Total (95% CI) 257 259 100.0 % 1.01 [ 0.30, 3.44 ]
Total events: 5 (Vitamin E), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours vitamin E
A P P E N D I C E S
Appendix 1. Source, search strategy and hits retrieved: June 2012 search
Source Search strategy Hits received
1. ALOIS (www.medicine.ox.ac.uk/alois) Advanced search: [Study design: RCT OR
CCT] AND [Health condition: Alzheimer
OR MCI] AND [Intervention: “vitamin
E”] (all dates)
Jun 2012: 39 (all dates)
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(Continued)
2. MEDLINE In-process and other non-
indexed citations and MEDLINE 1950 to
present (OvidSP)
1. *Vitamin E/
2. “vitamin E”.ti,ab.
3. “alpha-tocopherol”.ti,ab.
4. or/1-3
5. Alzheimer*.ti,ab.
6. Alzheimer Disease/
7. AD.ti,ab.
8. “cognit* impair*”.ti,ab.
9. MCI.ti,ab.
10. (AACI or memory or CIND or ARCD
or ACMI).ti,ab.
11. (“N-MCI” or “A-MCI” or “M-MCI”)
.ti,ab.
12. (nMCI or aMCI or mMCI).ti,ab.
13. (CDR adj2 “0.5”).ab.
14. or/5-13
15. 4 and 14
16. randomized controlled trial.pt.
17. controlled clinical trial.pt.
18. randomi?ed.ab.
19. placebo.ab.
20. drug therapy.fs.
21. randomly.ab.
22. trial.ab.
23. groups.ab.
24. or/16-23
25. (animals not (humans and animals)).
sh.
26. 24 not 25
27. 15 and 26
Jun 2012: 16
3. EMBASE
1980 to 2011 week 27 (OvidSP)
1. *Vitamin E/
2. “vitamin E”.ti,ab.
3. “alpha-tocopherol”.ti,ab.
4. or/1-3
5. Alzheimer*.ti,ab.
6. Alzheimer Disease/
7. AD.ti,ab.
8. “cognit* impair*”.ti,ab.
9. MCI.ti,ab.
10. (AACI or memory or CIND or ARCD
or ACMI).ti,ab.
11. (“N-MCI” or “A-MCI” or “M-MCI”)
.ti,ab.
12. (nMCI or aMCI or mMCI).ti,ab.
13. (CDR adj2 “0.5”).ab.
14. or/5-13
15. 4 and 14
16. randomi?ed.ab.
Jun 2012: 28
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(Continued)
17. placebo.ab.
19. trial.ab.
20. groups.ab.
21. randomized controlled trial/
22. controlled clinical trial/
23. (“double-blind*” or “single-blind*”).ti,
ab.
24. or/16-23
25. 15 to 24
4. PsycINFO
1806 to July week 2 2011 (OvidSP)
1. “vitamin E”.ti,ab.
2. “alpha-tocopherol”.ti,ab.
3. Alzheimer*.ti,ab.
4. Alzheimer Disease/
5. AD.ti,ab.
6. “cognit* impair*”.ti,ab.
7. MCI.ti,ab.
8. (AACI or memory or CIND or ARCD
or ACMI).ti,ab.
9. (“N-MCI” or “A-MCI” or “M-MCI”).
ti,ab.
10. (nMCI or aMCI or mMCI).ti,ab.
11. (CDR adj2 “0.5”).ab.
12. randomi?ed.ab.
13. placebo.ab.
14. randomly.ab.
15. trial.ab.
16. groups.ab.
17. (“double-blind*” or “single-blind*”).ti,
ab.
18. Clinical Trials/
19. 1 or 2
20. or/3-11
21. or/12-18
22. 19 and 20 and 21
Jun 2012: 6
5. CINAHL (EBSCOhost) S1 (MM “Vitamin E”)
S2 TX “vitamin E”
S3 TX “alpha-tocopherol”
S4 S1 or S2 or S3
S5 (MH “Alzheimer’s Disease”)
S6 TX AD OR alzheimer*
S7 “mild cognitive impairment”
S8 TX “cognit* impair*”
S9 TX AACI OR memory OR CINDOR
ARCD OR ACMI
S10 TX MCI
S11 TX nMCI OR aMCI OR mMCI
S12 S5 or S6 or S7 or S8 or S9 or S10 or
Jun 2012: 6
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(Continued)
S11
S13 S4 and S12
S14 TX random*
S15 TX placebo*
S16 TX trial
S17 TX groups
S18 TX RCT OR CCT
S19 (MH “Randomized Controlled Tri-
als”)
S20 S14 or S15 or S16 or S17 or S18 or
S19
S21 S13 and S20
S22 EM 2009
S23 EM 2010
S24 EM 2011
S25 S22 or S23 or S24
S26 S21 and S25
6. ISIWeb of Knowledge - all databases [in-
cludes: Web of Science (1945 to present);
BIOSIS Previews (1926 to present);MED-
LINE (1950 to present); Journal Citation
Reports]
#1 Topic=(alzheimer* OR AD OR MCI
OR memory OR cognitive OR “cognit*
impair*”) AND Topic=(“vitamin e” OR
“alpha-tocopherol”) AND Year Published=
(2009-2011)
Timespan=All Years
#2 Topic=(random* OR placebo* OR
“double-blind*” OR “single-blind*”)
Timespan=All Years
#3 #2 AND #1
Timespan=All Years
Jun 2012: 174
7. LILACS (BIREME) vitamin-e OR alpha-tocopherol Jun 2012: 0
8. CENTRAL (the Cochrane Library) (Is-
sue 4 of 4, Oct 2010)
#1 “vitamin e”
#2 “alpha-tocopherol”
#3 (#1 OR #2)
#4 MeSH descriptor Vitamin E, this term
only
#5 (#3 OR #4)
#6 alzheimer* OR AD OR “cognit* im-
pair*” OR MCI
#7 (#5 AND #6), from 2011 to 2012
Jun 2012: 9
9. Clinicaltrials.gov (
www.clinicaltrials.gov)
Interventional Studies | alzheimer OR
alzheimer’s OR alzheimers OR MCI OR
cognitiveOR cognitionORmemory | vita-
minEORalpha-tocopherol | received from
01/01/2011 to 07/15/2012
Jun 2012: 2
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10. ICTRP Search Portal (apps.who.int/
trialsearch) (includes: Australian New
Zealand Clinical Trials Registry; Clinical-
Trilas.gov; ISRCTN;Chinese Clinical Trial
Registry; Clinical Trials Registry - India;
Clinical Research Information Service - Re-
public of Korea; German Clinical Trials
Register; Iranian Registry of Clinical Tri-
als; Japan Primary Registries Network; Pan
African Clinical Trial Registry; Sri Lanka
Clinical Trials Registry; The Netherlands
National Trial Register)
Interventional Studies | alzheimer OR
alzheimer’s OR alzheimers OR MCI OR
cognitiveOR cognitionORmemory | vita-
minEORalpha-tocopherol | received from
01/07/2011 to 15/07/2012
Jun 2012: 2
TOTAL before de-duplication 282
TOTAL after de-duplication and first assessment 14
Appendix 2. Sources searched, search strategies and hits retrieved: October 2014, May 2015, April
2016
Source Search strategy Hits received
1. ALOIS (www.medicine.ox.ac.uk/alois) Advanced search: [Study design: RCT OR
CCT] AND [Health condition: Alzheimer
OR MCI] AND [Intervention: “vitamin
E”] (all dates)
Oct 2014: 11
May 2015: 0
Apr 2016: 0
2. MEDLINE In-process and other non-
indexed citations and MEDLINE 1950 to
present (OvidSP)
1. *Vitamin E/
2. “vitamin E”.ti,ab.
3. “alpha-tocopherol”.ti,ab.
4. or/1-3
5. Alzheimer*.ti,ab.
6. Alzheimer Disease/
7. AD.ti,ab.
8. “cognit* impair*”.ti,ab.
9. MCI.ti,ab.
10. (AACI or memory or CIND or ARCD
or ACMI).ti,ab.
11. (“N-MCI” or “A-MCI” or “M-MCI”)
.ti,ab.
12. (nMCI or aMCI or mMCI).ti,ab.
13. (CDR adj2 “0.5”).ab.
14. or/5-13
15. 4 and 14
16. randomized controlled trial.pt.
Oct 2014: 51
May 2015: 6
Apr 2016: 43
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17. controlled clinical trial.pt.
18. randomi?ed.ab.
19. placebo.ab.
20. drug therapy.fs.
21. randomly.ab.
22. trial.ab.
23. groups.ab.
24. or/16-23
25. (animals not (humans and animals)).
sh.
26. 24 not 25
27. 15 and 26
3. EMBASE
1980 to 2011 week 27 (OvidSP)
1. *Vitamin E/
2. “vitamin E”.ti,ab.
3. “alpha-tocopherol”.ti,ab.
4. or/1-3
5. Alzheimer*.ti,ab.
6. Alzheimer Disease/
7. AD.ti,ab.
8. “cognit* impair*”.ti,ab.
9. MCI.ti,ab.
10. (AACI or memory or CIND or ARCD
or ACMI).ti,ab.
11. (“N-MCI” or “A-MCI” or “M-MCI”)
.ti,ab.
12. (nMCI or aMCI or mMCI).ti,ab.
13. (CDR adj2 “0.5”).ab.
14. or/5-13
15. 4 and 14
16. randomi?ed.ab.
17. placebo.ab.
19. trial.ab.
20. groups.ab.
21. randomized controlled trial/
22. controlled clinical trial/
23. (“double-blind*” or “single-blind*”).ti,
ab.
24. or/16-23
25. 15 to 24
Oct 2014: 100
May 2015: 65
Apr 2016: 40
4. PsycINFO
1806 to July week 2 2011 (OvidSP)
1. “vitamin E”.ti,ab.
2. “alpha-tocopherol”.ti,ab.
3. Alzheimer*.ti,ab.
4. Alzheimer Disease/
5. AD.ti,ab.
6. “cognit* impair*”.ti,ab.
7. MCI.ti,ab.
8. (AACI or memory or CIND or ARCD
or ACMI).ti,ab.
Oct 2014: 10
May 2015: 4
Apr 2016: 0
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9. (“N-MCI” or “A-MCI” or “M-MCI”).
ti,ab.
10. (nMCI or aMCI or mMCI).ti,ab.
11. (CDR adj2 “0.5”).ab.
12. randomi?ed.ab.
13. placebo.ab.
14. randomly.ab.
15. trial.ab.
16. groups.ab.
17. (“double-blind*” or “single-blind*”).ti,
ab.
18. Clinical Trials/
19. 1 or 2
20. or/3-11
21. or/12-18
22. 19 and 20 and 21
5. CINAHL (EBSCOhost) S1 (MM “Vitamin E”)
S2 TX “vitamin E”
S3 TX “alpha-tocopherol”
S4 S1 or S2 or S3
S5 (MH “Alzheimer’s Disease”)
S6 TX AD OR alzheimer*
S7 “mild cognitive impairment”
S8 TX “cognit* impair*”
S9 TX AACI OR memory OR CINDOR
ARCD OR ACMI
S10 TX MCI
S11 TX nMCI OR aMCI OR mMCI
S12 S5 or S6 or S7 or S8 or S9 or S10 or
S11
S13 S4 and S12
S14 TX random*
S15 TX placebo*
S16 TX trial
S17 TX groups
S18 TX RCT OR CCT
S19 (MH “Randomized Controlled Tri-
als”)
S20 S14 or S15 or S16 or S17 or S18 or
S19
S21 S13 and S20
S22 EM 2009
S23 EM 2010
S24 EM 2011
S25 S22 or S23 or S24
S26 S21 and S25
Oct 2014: 7
May 2015: 5
Apr 2016: 3
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6. ISIWeb of Knowledge - all databases [in-
cludes: Web of Science (1945 to present);
BIOSIS Previews (1926 to present);MED-
LINE (1950 to present); Journal Citation
Reports]
#1 Topic=(alzheimer* OR AD OR MCI
OR memory OR cognitive OR “cognit*
impair*”) AND Topic=(“vitamin e” OR
“alpha-tocopherol”) AND Year Published=
(2009-2011)
Timespan=All Years
#2 Topic=(random* OR placebo* OR
“double-blind*” OR “single-blind*”)
Timespan=All Years
#3 #2 AND #1
Timespan=All Years
Oct 2014: 91
May 2015: 58
Apr 2016: 54
7. LILACS (BIREME) vitamin-e OR alpha-tocopherol Oct 2014: 1
May 2015: 0
Apr 2016: 0
8. CENTRAL (the Cochrane Library) (Is-
sue 4 of 4, Oct 2010)
#1 “vitamin e”
#2 “alpha-tocopherol”
#3 (#1 OR #2)
#4 MeSH descriptor Vitamin E, this term
only
#5 (#3 OR #4)
#6 alzheimer* OR AD OR “cognit* im-
pair*” OR MCI
#7 (#5 AND #6), from 2011 to 2012
Oct 2014: 33
May 2015: 15
Apr 2016: 0
9. Clinicaltrials.gov (
www.clinicaltrials.gov)
Interventional Studies | alzheimer OR
alzheimer’s OR alzheimers OR MCI OR
cognitiveOR cognitionORmemory | vita-
minEORalpha-tocopherol | received from
01/01/2011 to 07/15/2012
Oct 2014: 1
May 2015: 2
Apr 2016: 1
10. ICTRP Search Portal (apps.who.int/
trialsearch) (includes: Australian New
Zealand Clinical Trials Registry; Clinical-
Trilas.gov; ISRCTN;Chinese Clinical Trial
Registry; Clinical Trials Registry - India;
Clinical Research Information Service - Re-
public of Korea; German Clinical Trials
Register; Iranian Registry of Clinical Tri-
als; Japan Primary Registries Network; Pan
African Clinical Trial Registry; Sri Lanka
Clinical Trials Registry; The Netherlands
National Trial Register)
Interventional Studies | alzheimer OR
alzheimer’s OR alzheimers OR MCI OR
cognitiveOR cognitionORmemory | vita-
minEORalpha-tocopherol | received from
01/07/2011 to 15/07/2012
Oct 2014: 14
May 2015: 4
Apr 2016: 1
TOTAL before de-duplication Oct 2014: 321
May 2015: 159
Apr 2016: 142
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TOTAL after de-duplication and first assessment Oct 2014: 41
May 2015: 8
Apr 2016: 8
WH A T ’ S N E W
Date Event Description
7 April 2017 Amended Prisma diagram corrected
25 January 2017 New citation required and conclusions have changed An updated search was performed for this review on 22
April 2016. One additional study was included (Dysken
2014); the results and conclusions have changed. The
authors of the review have changed
25 January 2017 New search has been performed Update search performed 22 April 2016. One additional
study included;results and conclusions changed. Author
team has changed
H I S T O R Y
Date Event Description
25 June 2012 New citation required and conclusions have changed An update search was performed for this review on 15
July 2011 and 25 June 2012. One additional study
was included (Lloret 2009); the results and conclusions
have changed. The authors of the review have changed
15 July 2011 New search has been performed An update search was performed for this review on 15
July 2011
18 March 2009 New search has been performed Update search of 5 March 2009 retrieved new studies
for consideration for inclusion
25 April 2008 New citation required but conclusions have not
changed
In 2007, the scope of this review was broadened to
include both Alzheimer’s disease patients and patients
with mild cognitive impairment
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16 January 2007 New search has been performed Update 2007: one new study was included (Petersen
2005). The included study did not affect the results
as it also showed that vitamin E has no more signifi-
cant effect than placebo formild cognitive impairment.
The overall conclusion of the review has not changed
as there is not enough evidence to support the use of
vitamin E in the treatment of Alzheimer’s disease or
mild cognitive impairment
2 November 2006 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Original: NT drew up the protocol. M Isaac (MI) planned the review and protocol, selected studies, critiqued the trials, advised on
analyses, revised drafts of protocol and review and supervised the review process.
Update 2006: MI and Rebecca Quinn (RQ) reviewed and selected the included studies. MI extracted the data, performed the analysis
and wrote the draft. NT contributed to the text and supervised. The search was carried out by Dymphna Hermans.
Update 2012: NF and MI reviewed and selected the included studies. NF extracted the data and wrote the draft. Annalie R Clark
(AC), Jennifer Rusted (JR) and NT contributed to the text. JR and NT supervised. The search was carried out by Anna-Noel Storr.
Update 2016: NF andDL independently reviewed and extracted descriptive data from included studies. NF, NT and DL independently
extracted outcome data. NF wrote the initial draft. DL, MI and NF all contributed to the text. NT made the final decision on any
disagreements between authors. The search was carried out by Anna-Noel Storr.
D E C L A R A T I O N S O F I N T E R E S T
Nicolas Farina - None known
David Llewellyn - None known
Mokhtar Gad El Kareem Nasr Isaac- None known
Naji Tabet - None known
S O U R C E S O F S U P P O R T
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Internal sources
• Centre for Dementia Studies, Brighton & Sussex Medical School, UK.
External sources
• NIHR, UK.
This update was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the
Cochrane Dementia and Cognitive Improvement group. The views and opinions expressed therein are those of the authors and do
not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service or the Department of Health
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We included ’Summary of findings’ tables and GRADE evaluation.
The methods of the review were updated to comply with the most recent version of the Cochrane Handbook for Systematic Reviews of
Interventions (Version 5.1; Higgins 2011).
Since the June 2012 update, one new author DL has been added. AC and JR have been removed as authors.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Activities of Daily Living; Alzheimer Disease [∗drug therapy; mortality]; Antioxidants [adverse effects; ∗therapeutic use]; Cognition
[drug effects]; CognitiveDysfunction [∗drug therapy;mortality];Disease Progression;OutcomeAssessment (HealthCare); Randomized
Controlled Trials as Topic; Vitamin E [adverse effects; ∗therapeutic use]; alpha-Tocopherol [adverse effects; ∗therapeutic use]
MeSH check words
Humans
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